drugset / Trial / NCT06858839
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Timeline
- Start
- 2025-03-12
- Primary completion
- 2027-01-21
- Completion
- 2027-04-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maridebart Cafraglutide | Unknown | — | Subcutaneous |